5 completed, 4 unknown, 3 active not recruiting, 3 recruiting. 8 Phase 2, 6 Phase 3, 3 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Ropeginterferon alfa-2b: new trials by email Literature Review of Ropeginterferon alfa-2b trials Research Report on Ropeginterferon alfa-2b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-21 | 2026-10-21 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm | Phase 4 | Withdrawn | PharmaEssentia | 2026-08-01 | 2026-07-31 | |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) Ropeginterferon alfa-2b - Cutaneous T Cell Lymphoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 38 | 2025-08-27 | 2026-04-01 |
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| A Study to Evaluate P1101 in Japanese PV Patients P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 3 | Completed | PharmaEssentia Japan K.K. | 21 | 2023-10-17 | 2024-11-08 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities Ropeginterferon alfa-2b, SOC - COVID-19 | Phase 2 / Phase 3 | Unknown | National Taiwan University Hospital | 60 | 2023-05-15 | 2023-04-11 |
| A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide - Hepatitis D | Phase 2 | Unknown | National Taiwan University Hospital | 30 | 2023-02-24 | 2022-12-29 |
| Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) Ropeginterferon alfa-2b - Polycythemia Vera | Recruiting | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 429 | 2022-09-08 | 2026-07-09 | |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 | Active not recruiting | PharmaEssentia | 49 | 2021-10-08 | 2025-08-03 |
| Ropeginterferon Alfa 2b for Early Myelofibrosis Ropeginterferon alfa-2b - Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 50 | 2021-09-01 | 2022-10-06 |
| Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy Ropeginterferon alfa-2b, Entecavir - Chronic Hepatitis B Virus Infection | Not applicable | Unknown | National Taiwan University Hospital | 90 | 2021-05-04 | 2022-12-27 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia | Phase 3 | Active not recruiting | PharmaEssentia | 174 | 2020-08-25 | 2026-07-22 |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 2 | Completed | PharmaEssentia Japan K.K. | 29 | 2019-12-20 | 2025-09-15 |
| Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects ropeginterferon alfa-2b - Healthy Volunteers | Phase 1 | Completed | PharmaEssentia Japan K.K. | 36 | 2018-05-07 | 2019-11-26 |
| Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection P1101 + Ribavirin, PEG-Intron + Ribavirin - Chronic Hepatitis C Virus Infection | Phase 3 | Completed | PharmaEssentia | 222 | 2016-01-12 | 2022-01-18 |
| P1101 in Treating Patients With Myelofibrosis Laboratory Biomarker Analysis, Quality-of-Life Assessment, Ropeginterferon Alfa-2B - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 11 | 2015-08-12 | 2025-10-27 |
Myeloproliferative Disorders (6) · Polycythemia Vera (6) · Primary Myelofibrosis (3) · COVID-19 (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Hepatitis C, Chronic (1) · Hepatitis D (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, T-Cell, Cutaneous (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Thrombocythemia, Essential (1) · Thrombocytosis (1)
PharmaEssentia (6) · National Taiwan University Hospital (3) · PharmaEssentia Japan K.K. (3) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Merck Sharp & Dohme LLC (1) · The University of Hong Kong (1)
Taiwan (7) · United States (6) · China (4) · Japan (4) · Hong Kong (3) · South Korea (3) · Canada (2) · Singapore (2) · Australia (1) · Israel (1) · Italy (1) · Jordan (1) · Poland (1)
Toshiaki Sato, MD/PhD (2) · Chun-Jen Liu (1) · Craig Zimmerman, PhD (1) · Huang Yi-Wen, MD/PhD (1) · Jason Lickliter, MD (1) · Jeanne Palmer, M.D. (1) · Jingjing Zhang (1) · Pei-Jer Chen (1) · Wang-Huei Sheng, M.D. Ph.D (1) · Wanxing Chai-Ho, MD (1) · Yi-Wen Huang, MD/PhD (1) · Yumeng Zhang, MD (1)
PMID 40313042, PMID 33725322, PMID 35924546, PMID 37129584, PMID 37344895, PMID 38010606, PMID 41193116, PMID 41875235